2,6-dimethyl-terephthalamic acid | 7499-18-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-dimethyl-terephthalamic acid
• 英文别名: 2,6-Dimethyl-terephthalamidsaeure；4-Aminocarbonyl-2,6-dimethyl-benzoic Acid；4-carbamoyl-2,6-dimethylbenzoic acid
• CAS: 7499-18-5
• 化学式: C₁₀H₁₁NO₃
• 分子量: 193.202
• InChiKey: GDVBJIJUBPFSPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  2,6-dimethyl-terephthalamic acid 在 溴 作用下， 生成 4-氨基-2,6-二甲基苯甲酸
  参考文献：
  名称：

  Noyes, American Chemical Journal, 1898, vol. 20, p. 789

  摘要：

  DOI：
• 作为产物：
  描述：

  2,4,6-三甲基苯甲酸 在 盐酸 、 alkaline permanganate 作用下， 生成 2,6-dimethyl-terephthalamic acid
  参考文献：
  名称：

  Hufferd; Noyes, Journal of the American Chemical Society, 1921, vol. 43, p. 928

  摘要：

  DOI：

文献信息

• Piperazine derivatives useful as CCR5 antagonists
  申请人：Schering Corporation

  公开号：US06391865B1

  公开（公告）日：2002-05-21

  The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  公开了使用CCR5拮抗剂的公式，其中 R是可选择的取代苯基，吡啶基，噻吩基或萘基; R1是氢或烷基; R2是取代苯基，取代杂环基，萘基，芴基，二苯甲基或可选择的取代苯基或杂环基烷基; R3是氢，烷基，烷氧基烷基，环烷基，环烷基烷基，或可选择的取代苯基，苯基烷基，萘基，萘基烷基，杂环基或杂环基烷基; R4，R5和R7是氢或烷基; R6是氢，烷基或烯基; 用于治疗HIV，固体器官移植排斥，移植物宿主病，关节炎，类风湿关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化症的方法，以及包含它们的新化合物，包含它们的药物组合物，以及CCR5拮抗剂与抗HIV治疗中有用的抗病毒剂或与治疗炎症性疾病中有用的药物的组合。
• Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
  申请人：Syntex Inc.

  公开号：US05055451A1

  公开（公告）日：1991-10-08

  Thiol protease inhibitors are disclosed having the formula: ##STR1## or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, wherein: n is 0 or 1; m is 0, 1 or 2; X is H or an N-protecting group; each Y is independently an optionally protected .alpha.-amino acid residue; R is an optionally protected .alpha.-amino acid side chain that is H or CH.sub.3 or that is bonded to the .alpha.-carbon atom to which it is attached by a methylene, methine or phenyl radical; and R' is optionally substituted aryl.

  巯基蛋白酶抑制剂的结构式为：##STR1##或其光学异构体，或其药学上可接受的盐，其中：n为0或1；m为0、1或2；X为H或N-保护基；每个Y独立地是一个可选择保护的α-氨基酸残基；R是一个可选择保护的α-氨基酸侧链，可以是H或CH.sub.3，或者与其连接的α-碳原子通过亚甲基、亚烯基或苯基连接；R'是可选择取代的芳基。
• [EN] TROPANE COMPOUNDS<br/>[FR] COMPOSÉS DE TROPANE
  申请人：EXELIXIS INC

  公开号：WO2009055077A1

  公开（公告）日：2009-04-30

  A compound according to Formula I or II: (I) or (II) wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

  根据公式I或II的化合物：（I）或（II），其中R1、R1b、R2、L1和L2以及L2b的定义如规范中所述，以及其药物组合物和使用方法。
• Imaging of protease activity in live cells using activity based probes
  申请人：Bogyo S. Matthew

  公开号：US20070036725A1

  公开（公告）日：2007-02-15

  Methods and materials for the imaging of cells containing active proteases such as cathepsin are disclosed. The present materials include activity based probes that bind to an enzyme and are subsequently cleaved. Cleavage results in a fluorescent signal due to removal of a quenching group which, when present on the probe causes altered or no fluorescence. The probes employ an acyloxymethyl ketone reactive group, one or more amino acids for determining specificity, a fluorophore and a quencher. The probes are cell permeable and may use, for example, a QSY7 (diarylyrhodamine) quencher and a BODIPY (bora-diaza-indecene) dye.

  揭示了用于成像含有活性蛋白酶（如半胱氨酸蛋白酶）的细胞的方法和材料。目前的材料包括结合到酶并随后被切割的活性基团探针。切割导致荧光信号的产生，因为去除了一个熄灭基团，当存在于探针上时，会导致改变或无荧光。这些探针使用酰氧甲基酮反应基团，一个或多个氨基酸用于确定特异性，一个荧光团和一个熄灭剂。这些探针具有细胞穿透性，例如，可以使用QSY7（二芳基罗丹明）熄灭剂和BODIPY（硼二氮杂环庚烯）染料。
• Tropane compounds
  申请人：Rice Kenneth D.

  公开号：US20090163471A1

  公开（公告）日：2009-06-25

  A compound according to Formula I or II: wherein R 1 , R 1b , R 2 , L 1 , and L 2 and L 2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

  一种符合公式I或II的化合物：其中R1，R1b，R2，L1和L2以及L2b的定义如规范所述，以及其制药组成物和使用方法。